Healthcare resource utilization and exacerbations in patients with chronic obstructive pulmonary disease treated with glycopyrrolate/eFlow ® in the US: A real-world data analysis.
CONCLUSIONS: Among patients initiating GLY/eFlow in a real-world setting, COPD medications, hospitalizations, other HRU, and exacerbations decreased after treatment initiation compared with the 6-month pre-index period.
PMID: 33143516 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - Category: Health Management Tags: J Med Econ Source Type: research
More News: Asthma | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Economics | Health Management | Radiology | Study